Related Experiment Videos
BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics
1Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Japan.
Chest
|February 1, 1996
Summary
The TXA2 antagonist BAY u3405 significantly reduced bronchial hyperresponsiveness in asthma patients compared to placebo. This suggests BAY u3405 may be a beneficial treatment for asthma by attenuating airway hyperresponsiveness.
Area of Science:
- Pulmonology
- Pharmacology
- Immunology
Background:
- Thromboxane A2 (TXA2) is implicated in inducing bronchial hyperresponsiveness and bronchoconstriction.
- Asthma is characterized by bronchial hyperresponsiveness, a key factor in airway obstruction.
Purpose of the Study:
- To investigate the efficacy of the TXA2 antagonist BAY u3405 in mitigating methacholine-induced bronchial hyperresponsiveness in adult asthmatics.
- To evaluate the safety profile of BAY u3405 in this patient population.
Main Methods:
- A randomized, double-blind, placebo-controlled, crossover study involving 12 adult asthmatics.
- Subjects received either 75 mg of BAY u3405 or placebo orally, twice daily for 2 weeks, with a 2-week washout period.
- Bronchial hyperresponsiveness was assessed using the astograph method, measuring respiratory resistance (Rrs) response to incremental methacholine (MCh) concentrations to determine the minimum cumulative dose (Dmin).
Main Results:
- Three participants were withdrawn due to asthma exacerbations.
- The Dmin value was significantly higher after BAY u3405 treatment (0.533 U) compared to placebo (0.135 U) (p = 0.0139).
- No safety concerns were reported for either treatment.
Conclusions:
- BAY u3405 demonstrated a significant attenuation of bronchial hyperresponsiveness in asthmatic patients.
- The findings suggest that BAY u3405 holds potential as a therapeutic agent for managing bronchial asthma by reducing airway hyperresponsiveness.